Peroxiredoxin drugs for treatment of HIV-1 infection and methods of use thereof

Abstract

The invention includes compositions comprising substantially purified peroxiredoxin that are useful in methods for the treatment and prevention of HIV-1 infection. The invention also includes methods for the treatment and prevention of HIV-1 infection comprising contacting a composition of the invention with a human patient. Additionally, the invention includes antibodies and kits useful in the treatment and prevention of HIV-1 infection.

What we claim is:  
     
         1 . A method of treating HIV-1 infection, the method comprising contacting a cell susceptible to HIV-1 infection with an amount of peroxiredoxin sufficient to inhibit infection of the cell by HIV-1.  
     
     
         2 . The method of  claim 1 , wherein the peroxiredoxin is selected from the group consisting of type I peroxiredoxin and type II peroxiredoxin.  
     
     
         3 . The method of  claim 1 , wherein the peroxiredoxin is protease-resistant.  
     
     
         4 . A method of decreasing the infectivity of HIV-1, if any is present, in a biological sample, the method comprising: 
 (a) identifying a biological sample in which a reduction or elimination of HIV-1 infectivity is desirable; and    (b) contacting the biological sample with an amount of peroxiredoxin sufficient to decrease the infectivity of HIV-1 in the biological sample.    
     
     
         5 . The method of  claim 3 , wherein the biological sample is selected from the group consisting of: blood, plasma, serum, saliva, semen, cervical secretions, saliva, urine, breast milk, cell culture medium, and amniotic fluids.  
     
     
         6 . The method of  claim 3 , wherein the peroxiredoxin is selected from the group consisting of: type I peroxiredoxin and type II peroxiredoxin.  
     
     
         7 . The method of  claim 3 , wherein the peroxiredoxin is protease-resistant.  
     
     
         8 . The method of  claim 3 , wherein the amount of peroxiredoxin is at least about 5 μg/ml of the biological sample volume.  
     
     
         9 . The method of  claim 3  wherein the amount of peroxiredoxin is at least about 10 μg/ml of the biological sample volume.  
     
     
         10 . A method of treating HIV-1 infection, the method comprising contacting a cell susceptible to HIV-1 infection with an amount of manganese dismutase sufficient to inhibit infection of the cell by HIV-1.  
     
     
         11 . A method of treating HIV-1 infection, the method comprising introducing into a cell susceptible to HIV-1 infection a DNA molecule encoding a peroxiredoxin, and expressing the peroxiredoxin in an amount sufficient to inhibit infection of the cell by the HIV-1.  
     
     
         12 . A method of treating HIV-1 infection in a subject, the method comprising introducing into the subject a cell that expresses a peroxiredoxin in an amount sufficient to inhibit infection of an endogenous cell of the subject, the endogenous cell being susceptible to HIV-1 infection.  
     
     
         13 . A biological sample purification system to reduce the number of HIV-1 particles in a biological sample, comprising a peroxiredoxin linked to a surface.  
     
     
         14 . A biological sample purification system to reduce the number of HIV-1 particles in a biological sample, comprising a peroxiredoxin linked to a surface, wherein contacting said biological sample and said biological sample purification system results in a reduction in the number of HIV-1 particles present in the biological sample.  
     
     
         15 . The purification system of  claim 14 , wherein said surface is a bead, chip, column, or matrix.  
     
     
         16 . A pharmaceutical composition for the treatment or prevention of HIV infection in a subject, comprising a peroxiredoxin and a pharmaceutically acceptable carrier.  
     
     
         17 . A kit comprising in one or more containers the pharmaceutical composition of claim  16 .